Neuro-pharmacological studies on SB 5833, a new psychotherapeutic agent of the benzodiazepine class.
D000374:Aggression / Q000187:drug effects; D000661:Amphetamine / Q000037:antagonists & inhibitors; D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D001362:Avoidance Learning / Q000187:drug effects; D002219:Carbamates / Q000494:pharmacology; D002707:Chlordiazepoxide / Q000494:pharmacology; D003975:Diazepam / Q000031:analogs & derivatives / Q000494:pharmacology; D004357:Drug Synergism; D004569:Electroencephalography; D004597:Electroshock; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D009129:Muscle Tonus / Q000187:drug effects; D010424:Pentobarbital / Q000494:pharmacology; D010433:Pentylenetetrazole / Q000037:antagonists & inhibitors; D011817:Rabbits; D051381:Rats; D012640:Seizures / Q000517:prevention & control; D012890:Sleep / Q000187:drug effects; D013331:Strychnine / Q000037:antagonists & inhibitors
D014151:Anti-Anxiety Agents; D002219:Carbamates; D002707:Chlordiazepoxide; D000661:Amphetamine; D013331:Strychnine; D010424:Pentobarbital; D003975:Diazepam; D010433:Pentylenetetrazole